New white paper compares targeted resequencing strategies

Oxford, UK – 16 July 2013. OGT, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download white paper titled ‘When to use targeted re-sequencing — Choosing the right NGS method.’ The paper aims to assist researchers when planning NGS strategies by providing a detailed review of the major re-sequencing methods. Comparing and contrasting method suitability, the paper also examines the significant impact of data analysis, as well as time and cost considerations. OGT has written the white paper in response to a growing demand from within its customer base and the NGS community for a balanced and comprehensive guide to targeted re-sequencing strategies.

Considered from both clinical research and discovery viewpoints, the paper discusses whole exome and targeted panel sequencing strategies, without bias. This includes highlighting the limitations of each approach, and offering advice on when whole genome sequencing is appropriate, providing researchers with insight to identify the most suitable method for the task at hand. Considerations are also presented on choice of capture technologies, bait design and the use of service providers for method optimization and accessibility to meaningful results.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell^®, CytoSure^® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

For more information on the Company, please visit our website at ogt.com

CytoSure^®, SureSeq™ and myProbes^®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.